SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-185169"
 

Search: onr:"swepub:oai:DiVA.org:liu-185169" > The COVID-19 pandem...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Kronbichler, AndreasDepartment of Medicine, University of Cambridg, Cambridge, United Kingdom (author)

The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • Elsevier,2021
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-185169
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-185169URI
  • https://doi.org/10.1016/j.autrev.2021.102986DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:149196016URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:for swepub-publicationtype

Notes

  • The Coronavirus Disease 2019 (COVID-19) pandemic influenced the management of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. A paucity of data exists on outcome of patients with vasculitis following COVID-19, but mortality is higher than in the general population and comparable to patients undergoing haemodialysis or kidney transplant recipients (reported mortality rates of 20-25%). Delays in diagnosis have been reported, which are associated with sequelae such as dialysis-dependency. Management of ANCA-associated vasculitis has not changed with the aim to suppress disease activity and reduce burden of disease. The use of rituximab, an important and widely used agent, is associated with a more severe hospital course of COVID-19 and absence of antibodies following severe acute respiratory syndrome (SARS)-CoV-2 infections, which prone patients to re-infection. Reports on vaccine antibody response are scarce at the moment, but preliminary findings point towards an impaired immune response, especially when patients receive rituximab as part of their treatment. Seropositivity was reported in less than 20% of patients when rituximab was administered within the prior six months, and the antibody response correlated with CD19+ B-cell repopulation. A delay in maintenance doses, if disease activity allows, has been suggested using a CD19+ B-cell guided strategy. Other immunosuppressive measures, which are used in ANCA-associated vasculitis, also impair humoral and cellular vaccine responses. Regular measurements of vaccine response or a healthcare-policy time-based strategy are indicated to provide additional doses ("booster") of COVID-19 vaccines. This review summarizes a recent educational forum and a recent virtual meeting of the European Vasculitis Society (EUVAS) focusing on COVID-19.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Geetha, DuvuruDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA (author)
  • Smith, Rona MDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom (author)
  • Egan, Allyson C.Department of Medicine, University of Cambridge, Cambridge, United Kingdom (author)
  • Bajema, Ingeborg M.Department of Pathology, L1Q, Leiden University Medical Center, Leiden, the Netherlands (author)
  • Schönermarck, UlfDivision of Nephrology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany (author)
  • Mahr, AlfredDepartment of Rheumatology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland (author)
  • Anders, Hans-JoachimDivision of Nephrology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany (author)
  • Bruchfeld, AnnetteKarolinska Institutet,Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Njurmedicinska kliniken US,CLINTEC Karolinska Institutet, Stockholm, Sweden(Swepub:liu)anbru14 (author)
  • Cid, Maria C.Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, Institut dInvestigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (author)
  • Jayne, David R. W.Department of Medicine, University of Cambridge, United Kingdom (author)
  • Department of Medicine, University of Cambridg, Cambridge, United KingdomDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA (creator_code:org_t)

Related titles

  • In:Autoimmunity Reviews: Elsevier20:121568-99721873-0183

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view